Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product

Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose. Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose. OraFID® works with a couple of twists of the hands and ejects an exact number of minitablets. It is approved as an integral combination product for Flexilev®,...

OSLO, Norway, 27/06/2025 (informazione.news - comunicati stampa - salute e benessere)

Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose.

OraFID® works with a couple of twists of the hands and ejects an exact number of minitablets.
It is approved as an integral combination product for Flexilev®, Navamedic's medication for the treatment of Parkinson's.

The launch in Nordic markets is anticipated in October 2025 .

Kathrine Gamborg Andreassen , CEO, Mobile: +47 951 78 880 E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: Lars.Hjarrand@navamedic.com                                              

For more information, please visit

This information was brought to you by Cision http://news.cision.com

Navamedic ASA: First approval of the medical device OraFID® as primary package for a pharmaceutical product Oslo, Norway - 2025.06.27 - Navamedic announces that the Swedish Medical Products Agency, acting as News Powered by Cision

 

 

View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-first-approval-of-the-medical-device-orafid-as-primary-package-for-a-pharmaceutical-product-302493246.html